- Overview:
- This study evaluates the safety and effectiveness of a medication aiming to preserve function of insulin producing cells.
- Staus:
- Enrolling
- Clinical Description:
- A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D).
- Target Age/Sex:
- Ages 1 to 25, Male & Female
- Benefits:
- Participants will receive at no cost study-related exams, medications and medical care. You may be compensated for expense and travel.
- Study Length:
- About 24 weeks
- Link:
- ClinicalTrials.gov
